Drug Topics November 12, 2024
High copayments can be a structural barrier to medication therapy adherence.
Copayments may be a structural barrier to pulmonary vasodilator therapy adherence, with an association between higher copayments and medication adherence in adults receiving prostanoids and combination therapy for pulmonary arterial hypertension (PAH).
Although randomized controlled trials have demonstrated multiple benefits associated with endothelin receptor antagonists (ERA) and phosphodiesterase type-5 (PDE5) inhibitors combination therapy vs monotherapy, the economic burden of this treatment is substantial, with mean estimated costs topping $4500 per month.1
Due to the high costs of these medications, investigator used administrative claims data from insured individuals to evaluate the way in which medication copayment and household income relate to medication adherence in PAH. Study data were collected from...
Today's Sponsors
Today's Sponsor